Pradaxa: Experienced protection

In clinical trials for stroke prevention in AF, Pradaxa 150 mg BID remains the only NOAC to significantly reduce rates of ischemic stroke compared with warfarin in its respective study (RE-LY©)†‡§1–5

Protection through a proven safety profile1–5

Over 5 years of real-world experience6–10

Protection and treatment for 7 approved uses1

*In the USA, the licensed doses for Pradaxa are 150 mg BID and 75 mg BID for the prevention of stroke and systemic embolism in adult patients with non-valvular AF.
Relative risk reduction.
The above data is taken from the pivotal RE-LY trial where the primary endpoint was stroke or systemic embolism.11
§Pradaxa 110 mg twice daily, indicated for certain patients, was shown to be as effective as warfarin in preventing stroke or systemic embolism. These results were shown in the RE-LY trial, which was a PROBE (prospective, randomized, open-label with blinded endpoint) evaluation trial.11


  1. Pradaxa Summary of Product Characteristics 2015. Boehringer Ingelheim.
  2. Connolly SJ et al. N Engl J Med 2009;361(12):1139–1151.
  3. Connolly SJ et al. N Engl J Med 2010;363(19):1875–1876 (appendix).
  4. Connolly SJ et al. Circulation 2013;128:237–243.
  5. Connolly SJ et al. N Engl J Med 2014;371(15):1464–1465.
  6. Graham DJ et al. Circulation 2015;131:157–164.
  7. Seeger JD et al. Presented at AHA 2014.
  8. Villines TC et al. Presented at AHA 2014.
  9. Larsen TB et al. Am J Med 2014;127:650–656.
  10. Larsen TB et al. Am J Med 2014;127:329–336.
  11. Ezekowitz MD et al. Am Heart J 2009;157(5):805–810.